Efficacy and Safety of Long-term Oral Staphylococcus Albicans Tablets in Patients With Bronchiectasis

Official title

Efficacy and Safety of Long-term Oral Administration of Staphylococcus Albicans Tablets in Patients With Acute Exacerbation and Stable Bronchiectasis: a Multicenter, Prospective Randomized Controlled Clinical Trial

Overview

The main purpose of this study is to investigate whether long-term oral administration of Staphylococcus albicans tablets can significantly reduce the number of acute exacerbations in patients with bronchiectasis. Secondary objective is to explore whether long-term oral administration of Staphylococcus albicans tablets can reduce the risk of hospitalization in patients with bronchiectasis and whether it can improve the quality of life of patients. Other purpose is to explore the regulatory effect of long-term oral administration of Staphylococcus albicans tablets on the immune function of patients with bronchiectasis.

Detailed description

Bronchiectasis is a chronic airway purulent disease. The four factors of "vicious circle" play an important role in the occurrence, development and prognosis of bronchiectasis. Attempts to breaks the vicious circle may be beneficial to reduce the acute exacerbation of bronchiectasis. The main ingredients of Staphylococcus albicans tablets are the inactivated cells of Staphylococcus albus, Catarella catarrhalis and Bacillus subtilis. It may be beneficial to improve the non-specific immunity of patients and the specific immune function of respiratory mucosa, and reduce airway mucus secretion and secretion retention. There is not yet sufficient clinical evidence to support the immune function regulation and related efficacy of patients. Therefore, the efficacy of long-term oral administration of Staphylococcus albicans tablets in patients with bronchiectasis needs to be further confirmed by clinical studies.

Interventions

• Drug Staphylococcus and Neisseria Tablets
  0.3 mg/ tablet, 4 tablets each time, 3 times a day (Shandong Qilu Pharmaceutical Co., LTD.), the course of treatment was more than 3 months.
• Other On-demand treatment
  At the time of enrollment, patients with acute exacerbation of bronchiectasis were given routine treatment. For patients with stable bronchiectasis at the time of enrollment, they are treated as needed (that is, according to the needs of the disease, receive corresponding treatment).

Primary outcome measures

• Number of acute exacerbations [Time frame: Up to 12 months]
• Time to first exacerbation [Time frame: Up to 12 months]
• Rate of readmission at 12 months [Time frame: Up to 12 months]
• Number of acute exacerbations [Time frame: up to 6 months]
• Number of acute exacerbations [Time frame: Up to 3 months]

Secondary outcome measures (9)

• Change from Baseline Life Quality Score at 12 months [Time frame: Up to 12 months]
• Change from Baseline FEV1 at 12 months [Time frame: Up to 12 months]
• Change from Baseline FEV1/FVC at 12 months [Time frame: Up to 12 months]
• Change from Baseline FEV1 % predicted at 12 months [Time frame: Up to 12 months]
• Change from Baseline sputum volume at 12 months [Time frame: Up to 12 months]
• Change from Baseline percentage of patients with yellow purulent sputum at 12 months [Time frame: Up to 12 months]
• Change from Baseline percentage of patients with immune dysfunction at 12 months [Time frame: Up to 12 months]
• Change from Baseline of percentage of patients with positive sputum culture [Time frame: Up to 12 months]
• Number of Participants with adverse reactions [Time frame: Up to 12 months]

Eligibility criteria

Inclusion criteria

• Patients with bronchiectasis diagnosed by clinical manifestations and chest HRCT according to the diagnostic criteria for bronchiectasis;

• Patients with idiopathic or post-infectious bronchiectasis;

• 18years old;

• Patients should have at least 2 acute exacerbations within 1 year before enrollment;

• Patients in either acute exacerbation or stable period can be included.

Exclusion criteria

• Cystic fibrosis;

• Immunodeficiency, allergic bronchopulmonary aspergillosis, etc.;

• Traction bronchiectasis caused by severe emphysema or advanced pulmonary fibrosis;

• Still smoking;

• Complicated with asthma or chronic obstructive disease Lung;

• Patients with severe cardiovascular disease, severe neurological disease, or severe liver or kidney damage;

• Malignant tumors;

• Allergy to Staphylococcus albicans tablets;

• Patients with a history of gastric ulcer or intestinal malabsorption;

• Pregnant or lactating women;

• patients with poor compliance;

• previous (within 6 months before the start of the study) or concurrently taking immunostimulating drugs (including thymosin, interferon, transfer factor, BCG, pneumonia vaccine and any kind of bacteria Extracts, such as Biostim, except for influenza vaccine) or immunosuppressants;

• Patients who are participating in or have participated in interventional clinical trials within 3 months.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

China · 1 center

• Department of Respiratory, The First Affiliated Hospital of Shandong First Medical Univers — Jinan

Identifiers

NCT: NCT05407792 · 2022-5-26-QFS

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗